Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
William Kraus
Ut Southwestern Medical Center, Department: Obstetrics & Gynecology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ribon Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Kraus’ laboratory studies PARPs 1, 2 and 3 (nuclear PARPs with poly activity) in breast cancer, adipogenesis, stem cells, and inflammation. Ribon Therapeutics’ focus is on PARP16 and other non-nuclear PARPs with mono activity in blood cancers. The consulting agreement references that Dr. Kraus will provide services related to the discovery and development of modulators of Poly (ADP ribose) polymerases (PARP) for the treatment of cancer and other diseases. Services shall include, but not be limited to, providing interpretation and advice as to targets for therapy, efficient programs for the preclinical and clinical development of therapies, and effective means to explain the benefits of the Company’s technology to outside experts and non-experts.
The Role of PARP-1 in Hormone-Regulated Transcription
PARP-1 is an abundant nuclear enzyme that controls gene expression programs in a variety of signaling- and stress-related biological responses, including hormonal signaling, metabolism, inflammation, differentiation, adipogenesis, carcinogenesis, development, and aging. PARP-1 enzymatic activity can be targeted through chemical inhibition, and PARP inhibitors have shown promise in clinical trials for various cancers and inflammation-related diseases. Our proposed studies will shed new light on the molecular mechanisms of signal-dependent gene regulation by PARP-1 in key biological systems and may suggest better ways to target PARP-1 to prevent, diagnose, and treat human diseases.
Filed on June 19, 2015.
Tell us what you know about William Kraus's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
William Kraus filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| William Kraus | Ut Southwestern Medical Center | Conflict of Interest | Ribon Therapeutics | $0 - $4,999 |
| William Kraus | Ut Southwestern Medical Center | Conflict of Interest | Ribon Therapeutics | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.